One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis.

Saved in:
Bibliographic Details
Title: One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis.
Authors: Edwards CV; a Department of Hematology and Oncology, Boston Medical Center , Boston , MA , USA., Bhutani D; b Division of Hematology and Oncology, Columbia University Medical Center , New York , NY , USA., Mapara M; b Division of Hematology and Oncology, Columbia University Medical Center , New York , NY , USA., Radhakrishnan J; c Division of Nephrology, Columbia University Medical Center , New York , NY , USA., Shames S; d Division of Cardiology, Columbia University Medical Center , New York , NY , USA., Maurer MS; d Division of Cardiology, Columbia University Medical Center , New York , NY , USA., Leng S; b Division of Hematology and Oncology, Columbia University Medical Center , New York , NY , USA., Wall JS; e Graduate School of Medicine, University of Tennessee , Knoxville , TN , USA., Solomon A; e Graduate School of Medicine, University of Tennessee , Knoxville , TN , USA., Eisenberger A; b Division of Hematology and Oncology, Columbia University Medical Center , New York , NY , USA., Lentzsch S; b Division of Hematology and Oncology, Columbia University Medical Center , New York , NY , USA.
Source: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis [Amyloid] 2019; Vol. 26 (sup1), pp. 115-116.
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9433802 Publication Model: Print Cited Medium: Internet ISSN: 1744-2818 (Electronic) Linking ISSN: 13506129 NLM ISO Abbreviation: Amyloid Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1744-2818
DOI:10.1080/13506129.2019.1584892